Business Context and Reporting Period
Moleculin Biotech, Inc. (MBRX) filed a Form 8-K on February 18, 2026, to disclose a material update regarding its clinical development program. The filing focuses on the "MIRACLE" pivotal Phase 2B/3 study evaluating Annamycin in combination with cytarabine for adult patients with relapsed or refractory acute myeloid leukemia (R/R AML).
Key Financial Metrics
This filing is a Regulation FD disclosure regarding clinical trial progress and does not contain financial statements. Consequently, data regarding revenue, profit, cash flow, margins, debt, and liquidity are not provided in this document.
Material Changes and Clinical Progress
- Subjects Treated: As of February 10, 2026, 35 subjects have been treated in the MIRACLE study.
- Recruitment Status: An additional 11 subjects are currently in screening or have been identified.
- Milestone Target: The company aims to treat 45 subjects to trigger the first unblinding of data.
- Timeline: Management believes the company is on track to treat the 45th subject in the first quarter of 2026, with data unblinding to follow.
Outlook and Management Commentary
Management indicated that treatment, identification, and recruitment activities are ongoing. The company projects reaching the critical 45-subject threshold for initial data analysis within Q1 2026. No specific financial guidance or risk factors beyond standard clinical development uncertainties were detailed in this specific report.
Investor Verification Checklist
- Verify the actual date the 45th subject is treated to confirm the Q1 2026 timeline.
- Monitor subsequent filings for the results of the first data unblinding.
- Review the attached press release (Exhibit 99.1) for detailed protocol specifics not included in the 8-K summary.
- Check the company's most recent 10-Q or 10-K for current cash runway and burn rate, as this 8-K contains no financial data.